FR3079239A1 - Nouvelle methode d’obtention de cellules t a partir de cellules souches pluripotentes, et leurs utilisations - Google Patents

Nouvelle methode d’obtention de cellules t a partir de cellules souches pluripotentes, et leurs utilisations Download PDF

Info

Publication number
FR3079239A1
FR3079239A1 FR1852531A FR1852531A FR3079239A1 FR 3079239 A1 FR3079239 A1 FR 3079239A1 FR 1852531 A FR1852531 A FR 1852531A FR 1852531 A FR1852531 A FR 1852531A FR 3079239 A1 FR3079239 A1 FR 3079239A1
Authority
FR
France
Prior art keywords
cells
population
stem cells
cell
pluripotent stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
FR1852531A
Other languages
English (en)
French (fr)
Inventor
Carole GUILLONNEAU
Laurent David
Lea Flippe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Universitaire de Nantes
Nantes Université
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite de Nantes
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Universitaire de Nantes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite de Nantes, Institut National de la Sante et de la Recherche Medicale INSERM, Centre Hospitalier Universitaire de Nantes filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR1852531A priority Critical patent/FR3079239A1/fr
Priority to PCT/FR2019/050667 priority patent/WO2019180394A1/fr
Priority to US16/982,881 priority patent/US12054743B2/en
Priority to EP19718442.7A priority patent/EP3768828A1/fr
Priority to JP2020550615A priority patent/JP7464528B2/ja
Publication of FR3079239A1 publication Critical patent/FR3079239A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/99—Serum-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2303—Interleukin-3 (IL-3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/73—Hydrolases (EC 3.)
    • C12N2501/734—Proteases (EC 3.4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
FR1852531A 2018-03-23 2018-03-23 Nouvelle methode d’obtention de cellules t a partir de cellules souches pluripotentes, et leurs utilisations Pending FR3079239A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR1852531A FR3079239A1 (fr) 2018-03-23 2018-03-23 Nouvelle methode d’obtention de cellules t a partir de cellules souches pluripotentes, et leurs utilisations
PCT/FR2019/050667 WO2019180394A1 (fr) 2018-03-23 2019-03-22 Nouvelle méthode d'obtention de cellules t à partir de cellules souches pluripotentes, et leurs utilisations
US16/982,881 US12054743B2 (en) 2018-03-23 2019-03-22 Method for obtaining T cells from pluripotent stem cells, and uses thereof
EP19718442.7A EP3768828A1 (fr) 2018-03-23 2019-03-22 Nouvelle méthode d'obtention de cellules t à partir de cellules souches pluripotentes, et leurs utilisations
JP2020550615A JP7464528B2 (ja) 2018-03-23 2019-03-22 多能性幹細胞からｔ細胞を入手するための新規な方法およびその使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1852531 2018-03-23
FR1852531A FR3079239A1 (fr) 2018-03-23 2018-03-23 Nouvelle methode d’obtention de cellules t a partir de cellules souches pluripotentes, et leurs utilisations

Publications (1)

Publication Number Publication Date
FR3079239A1 true FR3079239A1 (fr) 2019-09-27

Family

ID=63557539

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1852531A Pending FR3079239A1 (fr) 2018-03-23 2018-03-23 Nouvelle methode d’obtention de cellules t a partir de cellules souches pluripotentes, et leurs utilisations

Country Status (5)

Country Link
US (1) US12054743B2 (https=)
EP (1) EP3768828A1 (https=)
JP (1) JP7464528B2 (https=)
FR (1) FR3079239A1 (https=)
WO (1) WO2019180394A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023501388A (ja) * 2019-11-08 2023-01-18 サンガモ セラピューティクス， インコーポレイテッド 操作された制御性ｔ細胞の生成
JP7825834B2 (ja) * 2021-01-20 2026-03-09 ソウル ナショナル ユニバーシティ アールアンドディビー ファウンデーション 抗ｃ４ｄキメラ抗原受容体調節性ｔ細胞およびその使用
KR20260047608A (ko) * 2023-08-04 2026-04-08 갓코호우징 도쿄리카다이가쿠 면역 세포의 제조 방법
CN118853569B (zh) * 2024-09-29 2025-03-04 星奕昂(上海)生物科技有限公司 一种拟胚体消化液及其在分离造血干细胞中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010051634A1 (en) * 2008-11-07 2010-05-14 Sunnybrook Health Sciences Centre Human progenitor t-cells
WO2014165707A2 (en) * 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
WO2017100403A1 (en) * 2015-12-08 2017-06-15 Regents Of The University Of Minnesota Human t cell derived from t cell-derived induced pluripotent stem cell and methods of making and using

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1784481A1 (en) 2004-08-25 2007-05-16 Technion Research And Development Foundation, Ltd. Methods of generating embryoid bodies using three dimensional scaffolds
WO2008101272A1 (en) * 2007-02-21 2008-08-28 Women's And Children's Health Research Institute Inc Method for obtaining treg-cells
KR101720961B1 (ko) * 2009-02-27 2017-03-29 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 다능성 세포의 분화
US20110027881A1 (en) * 2009-07-31 2011-02-03 St. Marianna University School Of Medicine Production method of immune cells
US8871510B2 (en) * 2009-12-03 2014-10-28 University Of Utah Research Foundation Methods for generating T lymphocytes from hematopoietic stem cells
WO2014180943A1 (en) 2013-05-08 2014-11-13 Vib Vzw Mcl-1 as critical regulator of foxp3+ regulatory t cell survival, and use thereof to treat severe immune disorders
FR3026744B1 (fr) * 2014-10-06 2024-04-19 Hopitaux Paris Assist Publique Methode de generation de progeniteurs de cellules t
WO2016123100A1 (en) * 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
WO2017173551A1 (en) * 2016-04-08 2017-10-12 The Governing Council Of The University Of Toronto Method for generating progenitor t cells from stem and/or progenitor cells and use of same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010051634A1 (en) * 2008-11-07 2010-05-14 Sunnybrook Health Sciences Centre Human progenitor t-cells
WO2014165707A2 (en) * 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
WO2017100403A1 (en) * 2015-12-08 2017-06-15 Regents Of The University Of Minnesota Human t cell derived from t cell-derived induced pluripotent stem cell and methods of making and using

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHIA-WEI CHANG ET AL: "Broad T-Cell Receptor Repertoire in T-Lymphocytes Derived from Human Induced Pluripotent Stem Cells", PLOS ONE, vol. 9, no. 5, 14 May 2014 (2014-05-14), pages e97335, XP055539276, DOI: 10.1371/journal.pone.0097335 *
LEI F ET AL: "T lineage differentiation from induced pluripotent stem cells", CELLULAR IMMUNOLOGY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 260, no. 1, 1 January 2009 (2009-01-01), pages 1 - 5, XP026733960, ISSN: 0008-8749, [retrieved on 20090915], DOI: 10.1016/J.CELLIMM.2009.09.005 *
R. HOLMES ET AL: "The OP9-DL1 System: Generation of T-Lymphocytes from Embryonic or Hematopoietic Stem Cells In Vitro", COLD SPRING HARBOR PROTOCOLS, vol. 2009, no. 2, 1 February 2009 (2009-02-01), XP055332733, DOI: 10.1101/pdb.prot5156 *

Also Published As

Publication number Publication date
JP2021518130A (ja) 2021-08-02
WO2019180394A1 (fr) 2019-09-26
US20210002612A1 (en) 2021-01-07
JP7464528B2 (ja) 2024-04-09
US12054743B2 (en) 2024-08-06
EP3768828A1 (fr) 2021-01-27

Similar Documents

Publication Publication Date Title
Selmani et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+ CD25highFOXP3+ regulatory T cells
US9206394B2 (en) Method for reconstructing immune function using pluripotent stem cells
Li et al. Umbilical cord tissue‐derived mesenchymal stem cells induce T lymphocyte apoptosis and cell cycle arrest by expression of indoleamine 2, 3‐dioxygenase
DK3183337T3 (en) Use of Jagged 1 / Frizzled 4 as cell surface marker for isolation of human cardiac ventricular progenitor cells
Hof-Nahor et al. Human mesenchymal stem cells shift CD8+ T cells towards a suppressive phenotype by inducing tolerogenic monocytes
Pulecio et al. Conversion of human fibroblasts into monocyte-like progenitor cells
US20220306988A1 (en) Induction of arterial-type of hemogenic endothelium (ahe) and enhancement of t cell production from pscs through overexpression of ets factors or modulating mapk/erk signalling pathways
CN103442724A (zh) 含有可从机体组织中分离的ssea-3阳性的多能干细胞的同种异体移植用细胞治疗用组合物
FR3079239A1 (fr) Nouvelle methode d’obtention de cellules t a partir de cellules souches pluripotentes, et leurs utilisations
CA3067551A1 (fr) Procede de production de progeniteurs erythroides
EP3548607A1 (en) Methods for isolating human cardiac ventricular progenitor cells
El Omar et al. Immunomodulation of endothelial differentiated mesenchymal stromal cells: impact on T and NK cells
Hussein et al. Multiple environmental signaling pathways control the differentiation of RORγt-expressing regulatory T cells
CN102884177B (zh) Cd49f通过pi3k/akt/gsk3途径促进成体干细胞的增殖、专能性和重编程
CN103459590A (zh) 可由机体的脐带或脂肪组织分离的多能干细胞
Mussar et al. Macrophage/epithelium cross-talk regulates cell cycle progression and migration in pancreatic progenitors
CN120641557A (zh) 来源于多能细胞的红系谱系
WO2016010153A1 (ja) 免疫細胞療法用ｔ細胞の誘導方法
Chang et al. Amniotic fluid stem cells with low γ-interferon response showed behavioral improvement in parkinsonism rat model
Dao et al. Comparing the immunosuppressive potency of naïve marrow stromal cells and Notch-transfected marrow stromal cells
WO2017159088A1 (ja) 移植用培養細胞または培養組織の調製方法
Vo et al. A novel tissue culture method to produce professional antigen-presenting cells from rainbow trout in vitro
Kim et al. Nox4-IGF2 Axis promotes differentiation of embryoid body cells into derivatives of the three embryonic germ layers
WO2023118752A1 (fr) Cellule progeniteur des lymphocytes t exprimant de maniere regulee un transgene d'interet
US20240084257A1 (en) Reagents and methods for producing erythromyeloid progenitor cells, nk cells, and megakaryocytes

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20190927

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

TQ Partial transmission of property

Owner name: NANTES UNIVERSITE, FR

Effective date: 20230803

Owner name: CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES, FR

Effective date: 20230803

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA, FR

Effective date: 20230803

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, FR

Effective date: 20230803

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8